Aggregator

On World No Tobacco Day, the World Health Organization (WHO) today launches a new publication and calls on governments to urgently ban all flavours in tobacco and nicotine products, including cigarettes, pouches, hookahs and e-cigarettes, to protect youth from addiction and disease.

Flavours like menthol, bubble gum and cotton candy are masking the harshness of tobacco and nicotine products turning toxic products into youth-friendly bait. Flavours not only make it harder to quit but have also been linked to serious lung diseases. Cigarettes, which still kill up to half of their users, also come in flavours or can have flavours added to them.

“Flavours are fuelling a new wave of addiction, and should be banned,” said Dr Tedros Adhanom Ghebreyesus, Director-General of WHO. “They undermine decades of progress in tobacco control. Without bold action, the global tobacco epidemic, already killing around 8 million people each year, will continue to be driven by addiction dressed up with appealing flavours.”

The publication, Flavour accessories in tobacco products enhance attractiveness and appeal, reveals how flavours and accessories like capsule filters and click-on drops are marketed to bypass regulations and hook new users.

Currently:

• over 50 countries ban flavoured tobacco;
• more than 40 countries ban e-cigarette sales; 5 specifically ban disposables and 7 ban e-cigarette flavours; and
• flavour accessories remain largely unregulated.

Countries such as Belgium, Denmark, and Lithuania are taking action, and WHO urges others to follow.

Flavours are a leading reason why young people try tobacco and nicotine products. Paired with flashy packaging and social media-driven marketing, they’ve increased the appeal of nicotine pouches, heated tobacco, and disposable vapes into addictive and harmful products, which aggressively target young people.

“We are watching a generation get hooked on nicotine through gummy bear-flavoured pouches and rainbow-coloured vapes,” said Dr Rüdiger Krech, WHO Director of Health Promotion. “This isn’t innovation, it’s manipulation. And we must stop it.”

WHO reiterates that tobacco products, including heated tobacco products, expose users to cancer-causing chemicals and should be strictly regulated.

The 2025 World No Tobacco Day campaign honours governments, youth activists and civil society leaders pushing back against industry interference. “Your actions are changing policy and saving lives,” said Dr Krech.

With around 8 million tobacco-related deaths each year, the time for action is now. Flavours, and the industries that deploy them, have no place in a healthy future.
 

The role of flavours in increasing the appeal of tobacco, nicotine and related products

Flavour accessories in tobacco products enhance attractiveness and appeal

Understanding the design features of tobacco, nicotine and related products and their possible effects

Manipulation and marketing strategies used by tobacco and nicotine industries to promote their products

The World Health Organization (WHO), Africa Centres for Disease Control and Prevention (Africa CDC), Robert Koch Institute (RKI) and the governments of Canada and the United Kingdom announced today the expansion of the successful Health Security Partnership to Strengthen Disease Surveillance in Africa (HSPA) to seven countries on the continent. 

Africa experiences more disease outbreaks than any other part of the world. While significant progress has been made in strengthening disease surveillance over the past decade, no country can tackle today’s complex health threats alone.

The Health Security Partnership strengthens disease surveillance and epidemic intelligence across the African continent, enabling countries to better detect and respond to public health threats - whether they are natural, accidental or deliberate. Launched in 2023 in six countries, The Gambia, Mali, Morocco, Namibia, South Africa and Tunisia, the partnership will expand to Rwanda in its second phase which runs from 2025 to 2028.

At the heart of the initiative is a collaborative surveillance approach that connects health and security sectors to reduce biological risks and strengthen surveillance systems nationally and internationally. HSPA is aligned with the health security objectives of the Global Partnership Against the Spread of Weapons and Materials of Mass Destruction and the Signature Initiative to Mitigate Biological Threats in Africa (SIMBA).

“HSPA represents an important step forward in building stronger partnerships for health security in Africa. By bringing together global, regional and national actors, this initiative supports countries in strengthening Collaborative Surveillance through mutual exchange and practical action. WHO remains committed to working alongside Member States to ensure that these collective efforts are well-coordinated, responsive, and rooted in national priorities,” said Dr Chikwe Ihekweazu, Acting WHO Regional Director for Africa; Deputy Executive Director, WHO Health Emergencies Programme.

The partnership is supporting countries to strengthen capacities in biorisk management, event and indicator-based surveillance, genomic surveillance and epidemic intelligence. This is achieved through training, guidance development, co-creation of implementation roadmaps, and hands-on technical assistance to ensure that implementation is aligned with country priorities, embedded within broader national systems, and built for long-term sustainability.
“Within the framework of this project, Africa CDC will work with the Member States in mobilizing political will for biosecurity and surveillance, establishing regional frameworks for bio-surveillance of high-consequence biological agents and toxins, and coordinating event-based surveillance. The collaboration with other partners and coordination with Member States is crucial especially in the current context of limited resources to strengthen the continent's capacity for early detection, response, and management of biological threats,” said Dr Raji Tajudeen, Acting Deputy Director General and Head, Division of Public Health Institutes and Research, Africa CDC.

The HSPA initiative has been supported from the start by the Government of Canada’s Weapons Threat Reduction Program, with additional funding in phase two from the Government of the United Kingdom.

Building on the achievements in phase one, the participating countries, with support from WHO and partners, will accelerate implementation to build a healthier, safer and more resilient Africa. 

On 29 May 2025, a correction was made to this news release, both in the headline and the main text, to reflect the joint announcement of the HSPA expansion with the governments of Canada and the United Kingdom, and to acknowledge HSPA’s alignment with the Global Partnership Against the Spread of Weapons and Materials of Mass Destruction and the Signature Initiative to Mitigate Biological Threats in Africa (SIMBA). 

The  Seventy-eighth World Health Assembly (WHA78), the annual meeting of World Health Organization’s (WHO) Member States, came to a close Tuesday, as health leaders lauded vast accomplishments and global solidarity.

The Assembly, WHO’s highest decision-making body, convened from 19 May to 27 May, under the theme “One World for Health”. Member States considered approximately 75 items and sub-items across all areas of health, engaging in lively debate and adopting consequential resolutions to improve health for all.

“The words ‘historic’ and ‘landmark’ are overused, but they are perfectly apt to describe this year’s World Health Assembly,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “The adoption of the Pandemic Agreement and the approval of the next increase in assessed contributions, along with the numerous other resolutions that Member States adopted are a sign to the world that we can achieve cooperation in the face of conflict, and unity amid division.”

On 20 May, Member States adopted the historic WHO Pandemic Agreement. The moment was met with heartfelt applause, celebrating over three years of intense negotiations by the Intergovernmental Negotiating Body, comprising WHO’s Member States.

The adoption of the Agreement is a once-in-a-generation opportunity to safeguard the world from a repeat of the suffering caused by the COVID-19 pandemic. The Agreement aims to enhance global coordination and cooperation, equity and access for future pandemics, all while respecting national sovereignty.

Over the next year, Member States will build on the Resolution, by holding consultations on the Pathogen Access and Benefit Sharing system (PABS), an annex to the Agreement which would enhance equitable access to medical advancements.

In a changing financial landscape, Member States united to protect WHO’s critical work by approving the second 20% increase in assessed contributions (ACs). By 2030–2031, ACs will make up 50% of WHO’s core budget, providing more predictable, resilient, and flexible funding.

The Assembly’s commitment to sustainable financing did not stop there; at a high-level pledging event during WHA78, health leaders pledged at least US$ 210 million for WHO’s Investment Round, the fundraising campaign for the Organization’s global health strategy for the next four years (the Fourteenth  General Programme of Work). In addition to the US$ 1.7 billion already raised for the Investment Round, these pledges mark a significant step toward sustainable financing of WHO. Since launching in May 2024, the Investment Round has attracted 35 new contributors – moving WHO closer to the broader donor base envisioned in the Director-General’s ongoing transformation agenda.

WHA 78 was steadfast in addressing ongoing health issues and adaptable in targeting threats and conflicts. The accomplishments of the Assembly spanned many areas of health as Member States 

• adopted a new resolution highlighting the global health financing emergency;
• endorsed first-ever resolutions on lung and kidney health, highlighting the upcoming UN General Assembly focus on noncommunicable diseases;
• adopted a new resolution on science-driven norms and standards for health policy and implementation;
• adopted a new target to halve the health impacts of air pollution by 2040; 
• adopted an innovative resolution to promote social connection with growing evidence linking it to improved health outcomes and reduced risk of early death; 
• adopted a resolution for a lead-free future;
• adopted a resolution to address rare diseases, protecting the over 300 million people globally who live with one of more than 7000 rare diseases;
• agreed to expand the provisions of the International Code of Marketing of Breast-milk Substitutes to tackle the digital marketing of formula milk and baby foods; 
• adopted a resolution to accelerate the eradication of Guinea worm disease.

The Assembly adopted other resolutions on digital health, the health and care workforce, medical imaging, nursing and midwifery, sensory impairment, and skin diseases, among others. Two new official WHO health campaigns were established: World Cervical Cancer Elimination Day and World Prematurity Day.

The World Health Assembly also discussed WHO’s work in health emergencies. Over the last year, WHO responded internationally to 51 graded emergencies across 89 countries and territories, including global outbreaks of cholera and mpox – a public health emergency of international concern – as well as multiple humanitarian crises. Working with over 900 partners across 28 health clusters, WHO helped provide health assistance for 72 million people in humanitarian settings. Nearly 60% of new emergencies were climate-related, highlighting the growing health impacts of climate change.

During the Assembly, Member States

• considered matters pertaining to WHO’s work in health emergencies and commended the Organization’s leadership in this space;
• noted the Director-General’s report on implementation of the health emergency prevention, preparedness, response and resilience (HEPR) framework and expressed their support for the strengthening of the global architecture;
• considered the health needs of people in Ukraine and the occupied Palestinian territory;
• noted the Director-General’s report on progress made in implementing the International Health Regulations (2005); and
• approved a resolution to strengthen the research base on public health and social measures to control outbreaks.

Note to editors

On 28 May 2025 a small change was made on the final bullet point of this news release, from "approved a decision to strengthen" to "approved a resolution to strengthen".

The Seventy-eighth World Health Assembly approved a decision to update the Global action plan (GAP) on antimicrobial resistance (AMR), for discussion at next year’s World Health Assembly (WHA79) in 2026.

An estimated 4.71 million deaths were associated with bacterial AMR as of 2021, according to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD). The GAP update will offer a practical framework for the next 10 years to achieve the targets and commitments included in the political declaration of the United Nations General Assembly High-Level Meeting on AMR in 2024 – including a 10% reduction in global deaths associated with bacterial AMR by 2030.

Since the global action plan was adopted in 2015, over 170 countries have developed multi-sectoral national action plans to address AMR. The updated plan will ensure the latest guidance is available to help countries accelerate implementation. It will reflect a multisectoral One Health approach, which aims to sustainably balance and optimize the health of people, animals and ecosystems.

WHO and the other Quadripartite organizations – the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP) and the World Organisation for Animal Health (WOAH) – will develop this update in consultation with Member States and relevant stakeholders.

The Seventy-eighth World Health Assembly also considered progress made in supporting countries to prevent infections; ensure universal access to quality and affordable diagnosis and appropriate treatment; strengthen surveillance, research and innovation; and enhance AMR awareness, governance and financing.

Looking ahead, other WHO priorities include supporting countries to achieve efficiencies by integrating AMR interventions in health sector planning and financing, and enhancing coordination and governance of the AMR response at all levels, including with the Quadripartite.

Related links

• A78/8: Antimicrobial resistance – Report by the Director-General
  

At the Seventy-eighth World Health Assembly in 2025, Member States expressed support for the first-ever draft Global action plan on climate change and health, marking an important step forward in global health and climate policy. The draft Global action plan 2025–2028 (EB156(40)) acknowledged the urgent need to address the health impacts of climate change, positioning health systems as part of the climate solution.

It aims to provide a strategic framework to guide Member States, the WHO Secretariat and other stakeholders in developing climate-resilient, low-carbon health systems; enhancing surveillance and early warning systems; protecting vulnerable populations; and integrating health into climate policy and financing mechanisms.

Building on commitments made at previous Conference of the Parties (COPs) and the outcomes of the Executive Board meeting in February 2025, this plan supports WHO’s work to promote health leadership in the global climate agenda and coordinate country-level action and implementation. By supporting this Global action plan, the Assembly affirmed that climate action is not only an environmental priority but also a strategic health priority.

While recognizing this important progress, some Member States noted that more time and dialogue are needed to reach consensus on certain principles and language used in the action plan moving forward.

Related links:

• Climate change and health: Draft Global Action Plan on Climate Change and Health A78/4 Add.2
• Documents A78/4, A78/4 Add.2 and EB156/2025/REC/1, decision EB156(40)
• Draft Global Action Plan on Climate Change and Health as contained in decision EB156(40) and
• EB156/25)